Cargando…

Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles

INTRODUCTION: Blood biomarkers represent a major advance for improving the management, diagnosis, and monitoring of Alzheimer's disease (AD). However, their context of use in relation to routine cerebrospinal fluid (CSF) analysis for the quantification of amyloid peptides and tau proteins remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Delaby, Constance, Alcolea, Daniel, Hirtz, Christophe, Vialaret, Jérôme, Kindermans, Jana, Morichon, Lisa, Fortea, Juan, Belbin, Olivia, Gabelle, Audrey, Blennow, Kaj, Zetterberg, Henrik, Lleó, Alberto, Lehmann, Sylvain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2022
Materias:	Neurology and Preclinical Neurological Studies - Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866346/ https://www.ncbi.nlm.nih.gov/pubmed/35169889 http://dx.doi.org/10.1007/s00702-022-02474-9

Ejemplares similares

Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer’s disease and are highly correlated with phospho-tau in control individuals
por: Lehmann, Sylvain, et al.
Publicado: (2020)

From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid
por: Hirtz, Christophe, et al.
Publicado: (2016)

Antibody-free quantification of seven tau peptides in human CSF using targeted mass spectrometry
por: Bros, Pauline, et al.
Publicado: (2015)

Admission Levels of Total Tau and β-Amyloid Isoforms 1–40 and 1–42 in Predicting the Outcome of Mild Traumatic Brain Injury
por: Hossain, Iftakher, et al.
Publicado: (2020)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies
por: Reyes-Leiva, David, et al.
Publicado: (2022)

Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification
por: Barthélemy, Nicolas R., et al.
Publicado: (2020)

The alternative proteome in neurobiology
por: Mohaupt, Pablo, et al.
Publicado: (2022)

Longitudinal Alterations of Alpha-Synuclein, Amyloid Beta, Total, and Phosphorylated Tau in Cerebrospinal Fluid and Correlations Between Their Changes in Parkinson's Disease
por: Dolatshahi, Mahsa, et al.
Publicado: (2018)

Comparison of ultrasensitive and mass spectrometry quantification of blood-based amyloid biomarkers for Alzheimer’s disease diagnosis in a memory clinic cohort
por: Hirtz, Christophe, et al.
Publicado: (2023)

β-Synuclein as a candidate blood biomarker for synaptic degeneration in Alzheimer’s disease
por: Mohaupt, Pablo, et al.
Publicado: (2022)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
por: Chen, Ting-Bin, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson’s disease: protocol for a systematic review and individual participant data meta-analysis
por: Eusebi, Paolo, et al.
Publicado: (2017)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Amyloid and tau PET in cerebral amyloid angiopathy-related inflammation two case reports and literature review
por: Yang, Jhih-Yong, et al.
Publicado: (2023)

Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data
por: Bos, Isabelle, et al.
Publicado: (2018)

24S-Hydroxycholesterol Correlates With Tau and Is Increased in Cerebrospinal Fluid in Parkinson's Disease and Corticobasal Syndrome
por: Björkhem, Ingemar, et al.
Publicado: (2018)

Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects
por: Gabelle, Audrey, et al.
Publicado: (2019)

ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer's Disease – Study Protocol and Baseline Characteristics
por: Snellman, Anniina, et al.
Publicado: (2022)

Shared CSF Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus and Subcortical Small Vessel Disease
por: Jeppsson, Anna, et al.
Publicado: (2022)

Peripheral Blood and Salivary Biomarkers of Blood–Brain Barrier Permeability and Neuronal Damage: Clinical and Applied Concepts
por: Janigro, Damir, et al.
Publicado: (2021)

C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease
por: García-Ayllón, María-Salud, et al.
Publicado: (2017)

Clinical Phenotyping and Biomarkers in Spinal and Bulbar Muscular Atrophy
por: Millere, Elina, et al.
Publicado: (2021)

Examining four blood biomarkers for the detection of acute intracranial abnormalities following mild traumatic brain injury in older adults
por: Iverson, Grant L., et al.
Publicado: (2022)

One-Year Prospective Study of Plasma Biomarkers From CNS in Patients With Mild Traumatic Brain Injury
por: Clarke, Gerard Janez Brett, et al.
Publicado: (2021)

Roles of Microglial and Monocyte Chemokines and Their Receptors in Regulating Alzheimer's Disease-Associated Amyloid-β and Tau Pathologies
por: Guedes, Joana R., et al.
Publicado: (2018)

Plasma Amyloid Beta and Tau Levels Are Predictors of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Chi, Nai-Fang, et al.
Publicado: (2019)

Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters
por: Schirinzi, Tommaso, et al.
Publicado: (2022)

Clinical, imaging, and biomarker evidence of amyloid- and tau-related neurodegeneration in late-onset epilepsy of unknown etiology
por: Hickman, L. Brian, et al.
Publicado: (2023)

Admission Levels of Interleukin 10 and Amyloid β 1–40 Improve the Outcome Prediction Performance of the Helsinki Computed Tomography Score in Traumatic Brain Injury
por: Posti, Jussi P., et al.
Publicado: (2020)

Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
por: Lennol, Matthew Paul, et al.
Publicado: (2022)

Serum erythropoietin and outcome after ischaemic stroke: a prospective study
por: Åberg, N David, et al.
Publicado: (2016)

Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults
por: Havdal, Lise Beier, et al.
Publicado: (2022)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Case report: Non-Alzheimer's disease tauopathy with logopenic variant primary progressive aphasia diagnosed using amyloid and tau PET
por: Momota, Yuki, et al.
Publicado: (2022)

What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France
por: Cognat, Emmanuel, et al.
Publicado: (2019)

Comparing Glial Fibrillary Acidic Protein (GFAP) in Serum and Plasma Following Mild Traumatic Brain Injury in Older Adults
por: Huebschmann, Nathan A., et al.
Publicado: (2020)

Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer’s disease continuum
por: Goossens, Julie, et al.
Publicado: (2023)

Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls
por: Pålsson, Erik, et al.
Publicado: (2017)

Correlations between cerebrospinal fluid homovanillic acid and dopamine transporter SPECT in degenerative parkinsonian syndromes
por: Goto, Ryoji, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kcfdkf1kbj1hmfsoo61bft2i3d